NCT06838741Enrolling by invitation
Effects of Virtual Reality and Otago Exercises in Parkinson's Disease Patients.
Comparison of Effects of Virtual Reality and Otago Exercises on Balance, Gait and Activities of Daily Living in Parkinson's Disease Patients.
Source: ClinicalTrials.gov · Last updated 21 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Parkinson's disease, the second most common neurological condition, significantly affects motor function, gait, balance, and daily living activities. There is a pressing need for advanced therapies that specifically address these challenges. This study explores the potential benefits of virtual reality and Otago exercises, which may enhance balance and gait by providing sensory feedback crucial for motor learning and relearning. The randomized clinical trial will enroll 74 participants with Parkinson's disease, selected through non-probability convenience sampling. After obtaining synopsis approval, participants will be randomly assigned to one of two groups: Group A will engage in Otago exercises, while Group B will participate in virtual reality sessions. Each treatment session will last for 25 minutes. To evaluate outcomes, various tools will be employed, including the Berg Balance Scale for static balance and the Timed Up and Go test for dynamic balance. The 6-Minute Walk Test will measure gait performance, and the Unified Parkinson Disease Rating Scale will assess activities of daily living. Data normality will be determined using the Kolmogorov-Smirnov test, with subsequent analyses employing either one-way ANOVA or the Kruskal-Wallis test, depending on data distribution, to draw meaningful conclusions regarding treatment efficacy.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 74 (estimated)
- First submitted
- 1 Jan 2025
- Start date
- 1 Oct 2024
- Primary completion date
- 2 May 2025
- Lead sponsor
- Riphah International University
- Diseases
- Parkinson disease
- NCT number
- NCT06838741
What you commit to
- Study type: Interventional
- Planned participants: 74
- From 1 Oct 2024 to the primary completion date, 2 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent surgery or any fracture.
- Any pathology that may impair therapy
- Joint pain or musculoskeletal problem that interfered with therapy (22).
Other
- Any visual and hearing impairments.
Who the study is looking for
- The age group of 50 to 70 years will be included (19).
- Both male and female (20) .
- Patients diagnosed with Parkinson's disease of Hoehn and Yahr stage (1-3)
- Patient should be able to stand 10 minutes at least without assistance.
- Patients should be able to walk with or without assistance.
- Mini mental score should be higher than 24
Age in the registry: 50 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| General hospital Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.